Compare Wahed FTSE USA Shariah ETF (HLAL) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Wahed FTSE USA Shariah ETF vs Merck & Co., Inc. — how do they compare? Wahed FTSE USA Shariah ETF trades at $71.24, while Merck & Co., Inc. trades at $126.24 (market cap $307.25B). The key difference: Merck & Co., Inc. pays a 2.73% dividend while Wahed FTSE USA Shariah ETF pays none. Which is the better fit depends on your goals.
| HLAL | MRK | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $73.60 | $129.52 |
52-Week Low | $54.05 | $77.60 |
Market Cap | — | $307.25B |
Enterprise Value | — | $350.66B |
Dividend Yield | — | 2.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HLAL trades at $70.22, down 0.17% on the day, with a bearish technical signal from moving averages and neutral oscillators. The stock faces resistance at $71 and support at $70. Key financial ratios including P/E, P/S, and ROE are unavailable in the current dataset, limiting fundamental assessment. A small dividend of $0.02 is scheduled for June 2026.
The outlook remains cautious due to weak technical momentum and incomplete fundamental data. Investment opportunity hinges on upcoming financial disclosures to validate valuation. Primary risks include market volatility and lack of recent business updates. Analyst sentiment appears neutral to bearish given the technical configuration.
Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamental performance. The company reported robust 2025 results with $65.01B revenue and $18.25B net income, beating EPS estimates in recent quarters. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while analyst consensus remains bullish with a $137.30 price target.
Outlook is positive driven by earnings momentum and strategic M&A, but risks include patent expirations and competitive pressures. The stock offers a dividend yield with upcoming payment, supporting income investors. Valuation multiples are elevated, requiring sustained growth to justify current levels amid macroeconomic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Wahed FTSE USA Shariah ETF
HLAL is an ETF that invests in Shariah-compliant US companies. It follows a rigorous screening process to exclude businesses involved in non-compliant activities like interest-based finance, alcohol, and gambling.
Read more on HLAL →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
